Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 589-597

  Ligibel, Jennifer A ^a   James O'Malley, A ^b   Fisher, Maxine ^c   Daniel, Gregory W ^c   Winer, Eric P ^a   Keating, Nancy L ^b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HEALTHCORE INC   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Fracture; Myocardial infarction; Stroke; Tamoxifen

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; BREAST CANCER; CANCER HORMONE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FRACTURE; HEART INFARCTION; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; STROKE; TAMOXIFEN;

EID: 84856210003     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1754-1     Document Type: Article

References (29)

1. American Cancer Society (2010) Cancer facts & figures 2010. American Cancer Society, Atlanta
2. HJ Burstein AA Prestrud J Seidenfeld H Anderson TA Buchholz NE Davidson KE Gelmon SH Giordano CA Hudis J Malin EP Mamounas D Rowden AJ Solky MR Sowers V Stearns EP Winer MR Somerfield JJ Griggs 2010 American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 3784 3796 20625130 10.1200/JCO.2009.26.3756
3. P Goss J Ingle S Martino N Robert H Muss 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793 1802 14551341 10.1056/NEJMoa032312 1:CAS:528:DC%2BD3sXosl2gtbc%3D (Pubitemid 37362955)
4. R Jakesz W Jonat M Gnant M Mittlboeck 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from ABCSG Trial 8 and the ARNO 95 Trial Lancet 366 455 462 16084253 10.1016/S0140-6736(05)67059-6 1:CAS:528: DC%2BD2MXntVeisLw%3D (Pubitemid 41111693)
5. RC Coombes LS Kilburn CF Snowdon R Paridaens RE Coleman SE Jones J Jassem CJ Van de Velde T Delozier I Alvarez L Del Mastro O Ortmann K Diedrich AS Coates E Bajetta SB Holmberg D Dodwell E Mickiewicz J Andersen PE Lonning G Cocconi J Forbes M Castiglione N Stuart A Stewart LJ Fallowfield G Bertelli E Hall RG Bogle M Carpentieri E Colajori M Subar E Ireland JM Bliss 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial Lancet 369 559 570 17307102 10.1016/S0140-6736(07)60200-1 1:CAS:528:DC%2BD2sXhvVGgsro%3D
6. M Colleoni A Giobbie-Hurder MM Regan B Thurlimann H Mouridsen L Mauriac JF Forbes R Paridaens I Lang I Smith J Chirgwin T Pienkowski A Wardley KN Price RD Gelber AS Coates A Goldhirsch 2011 Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study J Clin Oncol 29 1117 1124 21321298 10.1200/JCO.2010.31. 6455 1:CAS:528:DC%2BC3MXmtVyrs7s%3D
7. JF Forbes J Cuzick A Buzdar A Howell JS Tobias M Baum 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 18083636 10.1016/S1470-2045(07)70385-6
8. Ries L, Eisner M, Kosary C (2003) SEER cancer statistics review, 1975-2000. National Cancer Institute, Bethesda, MD
9. Center for Disease Control and Prevention, Department of Vital Statistics. http://www.cdc.gov/nchs/nvss/mortality/lcwk10.htm
10. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group 2005 Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 15639680 10.1016/S0140-6736(04)17666-6 (Pubitemid 40082147)
11. B Thurlmann A Keshaviah H Mouridsen L Mauriac 2005 BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer J Clin Oncol 23 511
12. R Coombes M Hall L Gibson R Paridaens 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 15014181 10.1056/NEJMoa040331 1:CAS:528:DC%2BD2cXitV2qtbc%3D (Pubitemid 38298988)
13. Amir E, Ocana A, Niraula S, Carlsson L, Scruga B (2010) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients. In: San Antonio Breast Cancer symposium, Edition San Antonio, TX
14. F Cuppone E Bria S Verma KI Pritchard S Gandhi P Carlini M Milella C Nistico E Terzoli F Cognetti D Giannarelli 2008 Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials Cancer 112 260 267 18041059 10.1002/cncr.23171 1:CAS:528:DC%2BD1cXhs12gsbk%3D
15. NL Keating AJ O'Malley MR Smith 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 4448 4456 16983113 10.1200/JCO.2006.06.2497 1:CAS:528:DC%2BD28XhtVyisrrK (Pubitemid 46630983)
16. TA Marciniak EF Ellerbeck MJ Radford TF Kresowik JA Gold HM Krumholz CI Kiefe RM Allman RA Vogel SF Jencks 1998 Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project JAMA 279 1351 1357 9582042 10.1001/jama.279.17.1351 1:STN:280:DyaK1c3ktFWqug%3D%3D (Pubitemid 28198801)
17. CN Klabunde AL Potosky JM Legler JL Warren 2000 Development of a comorbidity index using physician claims data J Clin Epidemiol 53 1258 1267 11146273 10.1016/S0895-4356(00)00256-0 1:STN:280:DC%2BD3M%2FptlSrtQ%3D%3D (Pubitemid 32007842)
18. ME Charlson P Pompei KL Ales CR MacKenzie 1987 A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 373 383 3558716 10.1016/0021-9681(87)90171-8 1:STN:280:DyaL2s7ms1GnsQ%3D%3D (Pubitemid 17055592)
19. S Schneeweiss JD Seeger M Maclure PS Wang J Avorn RJ Glynn 2001 Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data Am J Epidemiol 154 854 864 11682368 10.1093/aje/154.9.854 1:STN:280:DC%2BD3MnktlSguw%3D%3D (Pubitemid 33000813)
20. JF Farley CR Harley JW Devine 2006 A comparison of comorbidity measurements to predict healthcare expenditures Am J Manag Care 12 110 119 16464140
21. PR Rosenbaum DB Rubin 1984 Difficulties with regression analyses of age-adjusted rates Biometrics 40 437 443 6487727 10.2307/2531396 1:STN:280:DyaL2M%2FitlGqsg%3D%3D (Pubitemid 16273077)
22. RB D'Agostino Jr 1998 Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 2265 2281 9802183 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0. CO;2-B (Pubitemid 28466823)
23. AH Partridge A LaFountain E Mayer BS Taylor E Winer A Asnis-Alibozek 2008 Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 556 562 18180462 10.1200/JCO.2007.11.5451 1:CAS:528:DC%2BD1cXis1alsrc%3D (Pubitemid 351264348)
24. Coronary Drug Project Research Group 1980 Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project Group N Engl J Med 303 1038 1041 10.1056/NEJM198010303031804
25. J Curtis JC Larson E Delzell MA Brookhart SM Cadarette R Chlebowski S Judd M Safford DH Solomon AZ Lacroix 2011 Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials Med Care 49 427 435 21422960 10.1097/MLR.0b013e318207ed9e
26. H Joensuu K Holli H Oksanen R Valavaara 2000 Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer Breast Cancer Res Treat 63 225 234 11110056 10.1023/A:1006465732143 1:CAS:528:DC%2BD3MXovVem
27. NL Keating MB Landrum JM Brooks EA Chrischilles EP Winer K Wright R Volya 2011 Outcomes following local therapy for early-stage breast cancer in non-trial populations Breast Cancer Res Treat 125 803 813 20376555 10.1007/s10549-010-0865-4
28. MJ Hassett AJ O'Malley NL Keating 2009 Factors influencing changes in employment among women with newly diagnosed breast cancer Cancer 115 2775 2782 19365847 10.1002/cncr.24301
29. D Hershman R McBride JS Jacobson L Lamerato K Roberts VR Grann AI Neugut 2005 Racial disparities in treatment and survival among women with early-stage breast cancer J Clin Oncol 23 6639 6646 16170171 10.1200/JCO.2005.12.633 (Pubitemid 46190258)